Home Newsletters Extracellular Matrix News CSA Medical Announces Completion of Enrollment in Mechanism of Action Study Utilizing...

CSA Medical Announces Completion of Enrollment in Mechanism of Action Study Utilizing the RejuvenAir® System for COPD Patients with Chronic Bronchitis

0
CSA Medical, Inc. announced that all subjects have been enrolled in the RejuvenAir® System study. The aim of this study is to determine the mechanism by which Metered CryoSpray reduces the density of goblet cells responsible for over-producing mucus and observe re-growth of healthy cilia in the airways.
[CSA Medical, Inc. (Cision US, Inc.)]

Sorry, but the selected Zotpress account can't be found.

Press Release
Exit mobile version